{
    "cancer_info": {
        "cancer_name": "Adolescent and Young Adult (AYA) Cancers (Multiple Types)"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Pregnancy test (before each therapy cycle)",
            "Genetic counseling (BRCA, Lynch syndrome, TP53, SDH mutations)",
            "Psychosocial evaluation (trauma history, gender identity, support systems)",
            "Echocardiogram (pre-anthracyclines)",
            "Renal function monitoring (electrolytes, renal function tests for platinum-based chemo)",
            "Audiograms and tinnitus evaluation (cisplatin exposure)",
            "Semen analysis (pre-therapy fertility assessment)",
            "FSH/LH/AMH/estradiol tests (ovarian function evaluation)",
            "Health literacy assessment",
            "Advance care planning",
            "HPV vaccination (ages 9-26)",
            "Self-examination (skin, breasts, testicles)",
            "Ultrasound",
            "Shielded X-ray/MRI (avoid gadolinium in pregnancy)",
            "Neuropsychological assessment",
            "Sexual health screening (STI risk, contraception)",
            "Substance use evaluation",
            "Nutritional status assessment",
            "ECG",
            "Pulmonary function tests (DLCO/spirometry post-bleomycin/chest radiation)",
            "Thyroid function tests (TSH/free T4)",
            "Pituitary function tests",
            "Breast MRI (post-chest radiation)",
            "Low-dose CT (lung cancer screening for high-risk)",
            "Audiologic testing (baseline and periodic for cisplatin exposure)",
            "Uterine vascular insufficiency screening (post-pelvic RT)",
            "Growth hormone testing",
            "DEXA scan (osteoporosis screening)",
            "Mammogram (breast cancer screening post-RT)",
            "Reproductive hormone panels (annual for alkylator exposure)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Late Effects Risk Stratification",
            "risk_group": "High risk (Cardiomyopathy)",
            "treatment_plans": [
                {
                    "treatment_line": "Prevention",
                    "patient_subgroup": "Anthracycline >250 mg/m² + chest RT ≥15 Gy",
                    "plan_name": "Cardioprotection",
                    "plan_details": "Dexrazoxane administration",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Standard intervention"
                },
                {
                    "treatment_line": "Monitoring",
                    "patient_subgroup": "Anthracycline recipients",
                    "plan_name": "Cardiac surveillance",
                    "plan_details": "Annual echocardiogram + cardiac MRI",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Standard intervention"
                }
            ]
        },
        {
            "staging_criteria": "Late Effects Risk Stratification",
            "risk_group": "High risk (Breast cancer)",
            "treatment_plans": [
                {
                    "treatment_line": "Screening",
                    "patient_subgroup": "Chest radiation ≥20 Gy",
                    "plan_name": "Breast cancer surveillance",
                    "plan_details": "Breast MRI + mammogram starting at age 25 or 8 years post-RT",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Consensus recommendation"
                }
            ]
        },
        {
            "staging_criteria": "Late Effects Risk Stratification",
            "risk_group": "High risk (Infertility)",
            "treatment_plans": [
                {
                    "treatment_line": "Preservation",
                    "patient_subgroup": "Pre-therapy patients",
                    "plan_name": "Fertility preservation",
                    "plan_details": "Sperm banking (males), oocyte/embryo cryopreservation (females)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Protection",
                    "patient_subgroup": "Females receiving alkylators",
                    "plan_name": "GnRH agonists",
                    "plan_details": "Goserelin during chemotherapy (investigational efficacy)",
                    "nccn_evidence_category": "Category 3",
                    "nccn_recommendation_category": "Controversial"
                }
            ]
        },
        {
            "staging_criteria": "Disease-Specific Treatment",
            "risk_group": "AYA with Acute Lymphoblastic Leukemia (ALL)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Age 15-39 years",
                    "plan_name": "Pediatric-inspired regimen",
                    "plan_details": "CALGB 10403 protocol",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Disease-Specific Treatment",
            "risk_group": "AYA with Testicular Cancer",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "All stages",
                    "plan_name": "Cisplatin-based chemotherapy",
                    "plan_details": "BEP regimen (Bleomycin/Etoposide/Cisplatin)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard intervention"
                }
            ]
        },
        {
            "staging_criteria": "Disease-Specific Treatment",
            "risk_group": "AYA with Hodgkin Lymphoma (HL)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "All stages",
                    "plan_name": "Reduced radiation therapy",
                    "plan_details": "Proton therapy to mitigate secondary cancers",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Consensus recommendation"
                }
            ]
        },
        {
            "staging_criteria": "Pregnancy Management",
            "risk_group": "Pregnant AYA patients",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "2nd/3rd trimester",
                    "plan_name": "Chemotherapy protocol",
                    "plan_details": "Anthracyclines/platinum agents permitted; avoid 1st trimester",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Multidisciplinary management"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "AMH <0.5 ng/mL predicts high infertility risk (primary ovarian insufficiency)",
            "Elevated FSH/LH indicates premature ovarian insufficiency",
            "Troponin/BNP elevations signal early cardiac damage (anthracycline toxicity)",
            "TP53 mutations increase sarcoma/breast cancer risk (Li-Fraumeni syndrome)",
            "BRCA2/ATM/MSH2 mutations associate with early-onset colorectal cancer",
            "Microsatellite Instability (MSI) screens for Lynch syndrome",
            "PIK3CA mutations indicate radiation-associated breast cancer risk",
            "SDH mutations link to GIST/paraganglioma development"
        ]
    },
    "guideline_id": "（2025.V2）NCCN临床实践指南：青少年和年轻成年人肿瘤.txt"
}